Fresenius Medical Care (NYSE:FMS) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research note issued to investors on Friday. The firm set a “strong-buy” rating on the stock.

A number of other equities research analysts have also recently weighed in on FMS. Berenberg Bank initiated coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target for the company. Truist Financial raised their target price on Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Finally, Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $24.30.

Fresenius Medical Care Stock Performance

NYSE FMS opened at $22.38 on Friday. Fresenius Medical Care has a 1-year low of $17.93 and a 1-year high of $24.31. The company has a 50 day moving average of $22.24 and a 200-day moving average of $20.65. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The firm has a market cap of $13.13 billion, a price-to-earnings ratio of 18.50, a PEG ratio of 0.96 and a beta of 0.92.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Rhumbline Advisers raised its position in shares of Fresenius Medical Care by 6.7% during the second quarter. Rhumbline Advisers now owns 18,067 shares of the company’s stock worth $345,000 after acquiring an additional 1,128 shares during the last quarter. Caprock Group LLC acquired a new position in Fresenius Medical Care during the 2nd quarter valued at about $208,000. Koss Olinger Consulting LLC bought a new position in shares of Fresenius Medical Care in the 2nd quarter valued at about $286,000. Triasima Portfolio Management inc. boosted its stake in shares of Fresenius Medical Care by 27.4% in the 2nd quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company’s stock valued at $1,631,000 after purchasing an additional 18,360 shares during the last quarter. Finally, American Century Companies Inc. grew its position in shares of Fresenius Medical Care by 29.3% during the 2nd quarter. American Century Companies Inc. now owns 24,046 shares of the company’s stock worth $459,000 after buying an additional 5,445 shares during the period. 8.37% of the stock is currently owned by institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.